Navigation Links
Lilly Provides Statement in Response to Amylin Lawsuit
Date:5/16/2011

INDIANAPOLIS, May 16, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) has provided the following statement in response to a lawsuit and motion for temporary restraining order filed by Amylin Pharmaceuticals, Inc. against Lilly. The action was filed in the United States District Court for the Southern District of California.

"We believe the lawsuit is without merit and will vigorously defend our position," said Enrique Conterno, president of Lilly Diabetes. "Lilly has been and remains fully committed to fulfilling its obligations under its exenatide collaboration agreement with Amylin, as well as to complying with all laws and regulations. We look forward to building on the alliance's success achieved to date."

"Our mission as a company is to bring needed therapeutic solutions to patients," added Conterno. "Significant unmet need exists among patients with diabetes, and the condition's prevalence and complications from it are projected to rise sharply as we look to the future. Lilly has a strong heritage of bringing new diabetes innovations to the market and we know that patients and health care professionals want choices to treat this complex disease throughout its progression."

Since the alliance's inception, Lilly has devoted significant talent, resources, and know-how to the collaboration's efforts and has been instrumental in the success of the marketed medicine BYETTA® (exenatide injection) and in the development of BYDUREON (exenatide extended-release for injectable suspension), which received a positive opinion from the European Committee for Medicinal Products for Human Use (CHMP) in April. The alliance plans to submit a response to the U.S. Food and Drug Administration's complete response letter in the second half of 2011.

About BYETTA® (exenatide) injection

BYETTA was the first gluca
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Lilly USA, LLC Launches TruAssist for Patients
2. Lilly Oncology to Unveil Data From More Than 30 Studies at ASCO
3. Lilly Oncology to Present New Data on Nine of Its Pipeline Molecules at ASCO 2011
4. Amylin Pharmaceuticals Files Suit Against Eli Lilly
5. Eli Lilly and Company Invests $2.5 Million to Launch The Mind Trusts Grow What Works Campaign
6. U.S. District Court Order Maintains Patent Exclusivity for Lillys Cymbalta
7. Lilly and Medtronic Announce Drug-Device Collaboration for Parkinsons Disease
8. Lilly Declares Second-Quarter 2011 Dividend
9. Lilly Reports First-Quarter 2011 Results
10. Lilly Receives Complete Response Letter From FDA for Liprotamase for the Treatment of Exocrine Pancreatic Insufficiency
11. Avant Healthcare Marketing Receives 2010 Lilly Global Sustained Supplier Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)...  Ardelyx, Inc. (NASDAQ: ARDX ), a clinical-stage ... today announced that the Company will host its inaugural ... 1:00 pm EDT in New York City ... team will present an overview of the Company,s pipeline ... Phase 2b clinical trials for the treatment of patients ...
(Date:6/30/2015)... Fla. , June 30, 2015  July 4 th ... declaration of independence, and the spirit and people behind it. ... Foundation has partnered with USA Medical ... help increase funding for programs that empower independence for our ... country, and help more people afford their prescriptions. ...
(Date:6/30/2015)... WAYNE, Pa. , June 30, 2015 ... ("Egalet"), a fully integrated specialty pharmaceutical company ... pain treatments, today announced top-line results from ... study of Egalet-002, an abuse-deterrent, extended-release, oral ... for the management of pain severe enough ...
Breaking Medicine Technology:Ardelyx to Host Inaugural R&D Investor Day in New York City on July 14, 2015 2Hope For Heroes and USA Medical Card Make a Difference for Our Nation's Heroes 2Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 2Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 3Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 4Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 5
... Targeting Pro-Inflammatory,Protein -, GAITHERSBURG, Md., April 18, ... publication of preclinical,study data demonstrating a role ... nuclear DNA-binding protein, in the pathology,of systemic ... or lupus) and rheumatoid arthritis. Data to ...
... RIDGE, N.J., April 19, 2007 /PRNewswire-FirstCall/ --,VioQuest ... focused on acquiring, developing and,commercializing targeted cancer ... VQD- 002, a direct inhibitor of Akt,activation ... tumors.,Pre-clinical data was presented in a poster ...
Cached Medicine Technology:MedImmune Publishes New Data in Nature Immunology Demonstrating The,Role HMGB1 May Play in Systemic Autoimmune Diseases 2MedImmune Publishes New Data in Nature Immunology Demonstrating The,Role HMGB1 May Play in Systemic Autoimmune Diseases 3VioQuest Pharmaceuticals Announces Data Presentation for Its Akt,Inhibitor VQD-002, at American Association for Cancer Research,Annual Meeting 2VioQuest Pharmaceuticals Announces Data Presentation for Its Akt,Inhibitor VQD-002, at American Association for Cancer Research,Annual Meeting 3VioQuest Pharmaceuticals Announces Data Presentation for Its Akt,Inhibitor VQD-002, at American Association for Cancer Research,Annual Meeting 4VioQuest Pharmaceuticals Announces Data Presentation for Its Akt,Inhibitor VQD-002, at American Association for Cancer Research,Annual Meeting 5
(Date:6/30/2015)... ... June 30, 2015 , ... In the Spring of 2015, ... in the Sierra Nevada mountains measured zero for the first time since records have ... of one of its most sustained periods of increasing drought.” , In ...
(Date:6/30/2015)... ... ... America is in a health crisis. Today, 4 out of 5 Americans will ... The answer is simple and is at the core of every disease and dysfunction—stress. ... one million patients and, for the first time ever, gives readers and followers 12 ...
(Date:6/30/2015)... (PRWEB) , ... June 30, 2015 , ... Ticket Down is a reliable source for ... Stadium in Provo, Utah. This legendary band has been packing venues for years and ... have also released more than 20 albums in their career. While Journey is known ...
(Date:6/30/2015)... (PRWEB) , ... June 30, 2015 , ... According to ... article, early humans who lived three to four hundred thousand years ago likely ... health. By examining the chemical compounds in fossilized, ancient dental plaque, researchers were able ...
(Date:6/30/2015)... ... June 30, 2015 , ... ADVOCATE, the premier ... own Debby Mann, CPC, RCC, ROCC, Coding Documentation and Education Manager, was honored ... Recognition Award for her contribution to the RBMA Coding Subcommittee. , Ms. ...
Breaking Medicine News(10 mins):Health News:RainSoil launches water-retention product as drought spreads. 2Health News:RainSoil launches water-retention product as drought spreads. 3Health News:12 Easy-To-Follow Steps to Transform Body, Mind and Spirit 2Health News:Journey Tickets at The Stadium of Fire at Lavell Edwards Stadium in Provo, Utah: Ticket Down Slashes Ticket Prices for Journey on the 4th of July in Provo 2Health News:Recent Article Detailing Research on 400,000 Year Old Dental Plaque Shows Ancestral Understanding of Healthy Eating and Basic Oral Hygiene, Says Feiz Dental 2Health News:Recent Article Detailing Research on 400,000 Year Old Dental Plaque Shows Ancestral Understanding of Healthy Eating and Basic Oral Hygiene, Says Feiz Dental 3Health News:ADVOCATE’s Debby Mann Honored With Special Recognition Award 2
... research has found that travelers who are prone to ... risk by pulling on a pair of elastic support ... the evidence that compression stockings can prevent deep vein ... condition in which blood coagulates into small clots inside ...
... outcome, when a nurse, nurses an urge to kill. ... profession, was convicted of murdering two patients // and ... General Hospital in Oxfordshire. ,The accused had injected ... caused the patients’ to stop breathing.Geen had committed these ...
... high time somebody spoke of retirement blues. A study ... retirement despondency claims three important factors that measure a ... outlook physical health and pension, in that order. Surprisingly, ... list for a happy retirement. ,The study tracked ...
... Concerns have been raised about the alarming rate of ... According to official estimates, about 6% of Australian children ... ,VicHealth, one of the important health promotion bodies of ... to curb childhood obesity. Additionally, it has pointed out ...
... who develop pre-eclampsia, which are a condition of abnormally high ... a stroke during pregnancy. // But new studies by ... and Prevention now report that pre-eclampsia is also a risk ... Brown and colleagues in Atlanta used data from the Stroke ...
... is better than Tamoxifen in preventing breast cancer in ... said that both drugs reduce the risk of cancer ... trial show that Eli Lilly and Co's Evista, known ... could prompt clinicians to replace Tamoxifen with Evista in ...
Cached Medicine News:Health News:Travel-Related Blood Clots Can Be Reduced By Using Flight Stockings 2
... The Apollo Knee System has been ... through range of motion of any fixed ... area and low contact stress under loading ... contributes to long-term effectiveness. The universal symmetrical ...
The Advance revision knee system was designed to address the unpredictable nature of revision knee arthroplasty by providing a wide variety of implant and instrument options....
The AGC dual articular knee is indicated for severe primary or revision cases and features a patented unique articulation which allows controlled rotation of the femoral component about a central piv...
... NexGen CRA femoral component is intended ... anteroposterior, and varus/valgus ligament stability, yet ... to inadequate bone stock. The NexGen ... a PMMA precoat surface. This device ...
Medicine Products: